Immutep completes patient enrolment for Phase II trial of eftilagimod alpha in metastatic breast cancer
Immutep Limited, a clinical-stage biotechnology company specializing in advanced LAG-3 immunotherapies, has announced the completion of patient enrolment for its Phase II AIPAC-003 clinical trial. ... Read More
Sermonix Pharmaceuticals awarded U.S. patent for lasofoxifene in breast cancer treatment
Sermonix Pharmaceuticals Inc., a leader in biopharmaceutical innovations, has achieved a significant milestone with the issuance of a new U.S. patent that broadens the application ... Read More
G1 Therapeutics’ Phase 3 trial of trilaciclib for metastatic triple negative breast cancer continues as planned
In a significant update for the oncology community, G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage company specializing in cancer treatment, announced the continuation of its ... Read More
Zydus Lifesciences gains FDA approval for Cyclophosphamide Capsules
Zydus Lifesciences Limited, a leading pharmaceutical company, has achieved a significant milestone by receiving final approval from the United States Food and Drug Administration (USFDA) ... Read More
Menarini’s EMERALD study of ORSERDU in breast cancer shows promising results
The Menarini Group and its subsidiary, Stemline Therapeutics, Inc., have made a significant stride in breast cancer treatment with new findings from the pivotal EMERALD ... Read More
Genentech’s Phase 3 study of inavolisib in breast cancer reveals positive results
Genentech, part of the Roche Group, has presented compelling results from the Phase III INAVO120 study, evaluating the effectiveness of inavolisib in combination with palbociclib ... Read More
Exai Bio says novel RNA and AI-driven platform can detect early breast cancer
Exai Bio, a leader in healthcare innovation, announced groundbreaking data showcasing the efficacy of its novel RNA-based and AI-driven liquid biopsy platform in detecting breast ... Read More
Roche’s inavolisib meets primary endpoint of PFS in Phase 3 breast cancer trial
Roche, a global leader in pharmaceuticals, announced positive results from its Phase III INAVO120 study, testing the investigational therapy inavolisib in combination with palbociclib (Ibrance) ... Read More
FDA approves AstraZeneca’s Truqap for advanced breast cancer treatment
In a notable development in the field of oncology, the US Food and Drug Administration (FDA) has approved AstraZeneca’s Truqap (capivasertib) in combination with Faslodex ... Read More
Gilead’s Trodelvy gains EC approval as new hope for metastatic breast cancer patients
In a significant advancement for cancer treatment, the European Commission (EC) has approved Gilead Sciences' Trodelvy (sacituzumab govitecan) for the treatment of adult patients suffering ... Read More